Abstract: Embodiments are disclosed for improving failure recovery in a distributed system during execution of a processing chain. In the context of a method, an example embodiment includes implementing, by the distributed system, a task coordination state machine corresponding to the processing chain. This example embodiment of the method further includes discovering, using the task coordination state machine, an error occurring during execution of the processing chain. Finally, the example embodiment of the method further includes reporting the error by a failure report generator service and recovering, by a failure recovery service, from the error. Corresponding apparatuses and computer program products are also provided.

Abstract: Embodiments are disclosed for improving failure recovery in a distributed system during execution of a processing chain. In the context of a method, an example embodiment includes implementing, by the distributed system, a task coordination state machine corresponding to the processing chain. This example embodiment of the method further includes discovering, using the task coordination state machine, an error occurring during execution of the processing chain. Finally, the example embodiment of the method further includes reporting the error by a failure report generator service and recovering, by a failure recovery service, from the error. Corresponding apparatuses and computer program products are also provided.

Abstract: A polypeptide comprising an androgen binding region, the androgen binding region capable of binding to an androgen at a sufficient affinity or avidity such that upon administration of the polypeptide to a mammalian subject the level of biologically available androgen is decreased. Specifically disclosed is an AR IgG1 Fc fusion protein, comprising the androgen binding domain of human androgen receptor and the Fc region of IgG. This fusion protein is used in the treatment of prostate cancer and testosterone flare.

Abstract: A polypeptide comprising an androgen binding region, the androgen binding region capable of binding to an androgen at a sufficient affinity or avidity such that upon administration of the polypeptide to a mammalian subject the level of biologically available androgen is decreased.

Abstract: An emergency window opening system includes a vehicle, a vehicle door attached to the vehicle and a window mounted in the vehicle door. A primary window motor is mechanically coupled to a lift gear mechanically coupled to the window to allow selective raising or lowering of the window. A housing is mounted within the vehicle door. A secondary motor is mounted within the housing. A drive shaft of the secondary motor is mechanically coupled to the lift gear. The secondary motor lowers the window when turned on. An actuator is mounted on the vehicle door and is electrically coupled by a wire to the secondary motor. The secondary motor is turned on when the actuator is actuated. A power supply line extends between and directly electrically couples a battery to the secondary motor. The power supply line extends into the housing.

Abstract: The present invention provides a polypeptide comprising an estrogen or androgen binding region, the binding region capable of binding to an estrogen or androgen at a sufficient affinity or avidity such that upon administration of the polypeptide to a mammalian subject the level of biologically available estrogen or androgen is decreased. The invention also provides for the treatment or prevention of cancers such as ovarian cancer, breast cancer and endometrial cancer using the polypeptides.

Abstract: A polypeptide comprising an androgen binding region, the androgen binding region capable of binding to an androgen at a sufficient affinity or avidity such that upon administration of the polypeptide to a mammalian subject the level of biologically available androgen is decreased. Specifically disclosed is an AR IgG1 Fc fusion protein, comprising the androgen binding domain of human androgen receptor and the Fc region of IgG. This fusion protein is used in the treatment of prostate cancer and testosterone flare.

Abstract: The present invention discloses the use of selenate or its pharmaceutically acceptable salts, especially in supranutritional amounts, in methods and compositions for inhibiting the growth or proliferation of tumor cells. The present invention also discloses the use of selenate or its pharmaceutically acceptable salts in combination with one or both of a hormone ablation therapy and a cytostatic agent or cytotoxic agent, for inhibiting the growth or proliferation of tumor cells. In certain embodiments, the methods of the invention are useful for treating or preventing cancers, especially cancers in which the Akt signaling pathway is activated, such as prostate cancer. Additionally, the present invention discloses the use of selenate or its pharmaceutically acceptable salts in combination with a hormone-ablation therapy and optionally a cytostatic agent or cytotoxic agent in methods and compositions for treating hormone- dependent cancers.